Keros Therapeutics, Inc. current report, 12 December 2022

Full document

Business Context and Reporting Period

Keros Therapeutics, Inc. (KROS) filed a Form 8-K on December 12, 2022, reporting on clinical data presentations at the 64th American Society of Hematology Annual Meeting and Exposition. The company is an emerging growth company focused on developing therapies for blood disorders.

Key Financial Metrics

This filing is a Current Report on Form 8-K regarding "Other Events" and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes

The material event reported is the presentation of new clinical and preclinical data:

  • KER-050 (MDS): Additional data from the ongoing Phase 2 trial in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes.
  • KER-050 (Myelofibrosis): Initial data from the ongoing Phase 2 trial in patients with myelofibrosis.
  • KER-047 (IRIDA): Initial data from the ongoing Phase 2 trial in patients with iron-refractory iron deficiency anemia.
  • Preclinical Data: Results showing the potential of a research form of KER-050 (RKER-050) to treat anemia and bone loss in an animal model of MDS, and data on the combination of activin receptor-like kinase 2 inhibition with RKER-050 in a mouse model of anemia of inflammation.

Guidance, Outlook, and Management Commentary

Management scheduled a conference call and webcast for December 12, 2022, to discuss the clinical results. The filing incorporates by reference a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2) containing the detailed data and management commentary. No specific financial guidance or forward-looking revenue projections are included in the text of this 8-K.

Investor Verification Checklist

  • Review the attached press release (Exhibit 99.1) for specific efficacy and safety statistics from the Phase 2 trials.
  • Examine the investor presentation (Exhibit 99.2) for detailed preclinical data on RKER-050 and combination therapies.
  • Verify the timeline for future clinical milestones based on the data presented at the ASH meeting.
  • Check subsequent filings (e.g., 10-Q or 10-K) for the financial impact of these clinical developments on the company's cash burn and funding needs.